The Director General of the National Institute for Pharmaceutical Research and Development (NIPRD), Dr Obi Adigwe, revealed the institute’s new focus on science, technology, innovation as well as local and international partnerships.
The NIPRD boss said the agency is now focusing on health equity in Nigeria through research and development (R&D) for local drug production and drug safety, noting that Tropical diseases such as malaria remain major health problems in the country.
Dr Adigwe, who made the observations at the Industrial Pharmacists Association of Nigeria (NAIP) 24th Annual National Conference, said noncommunicable and emerging diseases such as Ebola and COVID-19 were steadily increasing in Nigeria and in many African countries and needed research. to control them.
He informed that the country’s pharmaceutical research sector has developed three COVID-19 products, while at least 10 other products are awaiting adoption by the industry.
The innovation, he said, informed the huge investment being made at NIPRD to spur artificial intelligence and machine learning projects in drug discovery and phytomedicine development.
He said the intervention will exponentially improve relevant outcomes while preserving scarce resources in our research and development framework.
According to Adigwe, the recent investment in bioavailability and bioequivalence infrastructure was aimed at obtaining high quality Nigerian products with the hope of dominating the continent once the implementation of the African Continental Free Trade Area (AfCFTA) will accelerate.
It called on experts from the pharmaceutical industry to join the NIPRD active pharmaceutical ingredients (APIs) and excipients production project.
Meanwhile, Dr Adigwe and NIPRD Director of Research and Development Prof. Martins Emeje were honored for leading a new organization that leverages modern technologies to produce new products.